Your session is about to expire
← Back to Search
Monophasic Action Potential (MAP) Catheter for Ventricular Tachycardia
N/A
Waitlist Available
Led By Neal Bhatia, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during ablation on day 1
Awards & highlights
Study Summary
This trial will study the electrical properties of heart tissue to better understand ventricular arrhythmias and identify potential areas that may cause them.
Eligible Conditions
- Ventricular Tachycardia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during ablation on day 1
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during ablation on day 1
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Conduction Velocity
Waveform Morphology
Secondary outcome measures
Identify mechanisms of slowed conduction at ILAM
Identify surrogate markers
Trial Design
1Treatment groups
Experimental Treatment
Group I: Monophasic Action Potential (MAP) CatheterExperimental Treatment1 Intervention
Participants undergoing ventricular tachycardia ablation per standard of care will also have cellular action potential of the ventricular myocardium assessed with the MAP catheter.
Find a Location
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,645 Previous Clinical Trials
2,564,540 Total Patients Enrolled
Neal Bhatia, MDPrincipal InvestigatorEmory University
1 Previous Clinical Trials
80 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger